Greg Hurlbut

Greg is co-founder of Sionna and serves as Senior Vice President of Discovery Research. Formerly, he was the Head of Protein Conformational Diseases and Rare Pulmonary Diseases Research at Sanofi Genzyme. Greg’s research has led to a novel strategy for discovering small molecules that directly address the molecular pathology of the most common cystic fibrosis-causing mutation, ∆F508-CFTR. He was the Principal Investigator for $32 million in grant funding from the Cystic Fibrosis Foundation Therapeutics Development Initiative to support CF drug discovery and preclinical development.

Greg also served as an adjunct faculty member in the Department of Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School. Greg received his Ph.D. in cell and molecular biology from Université Paris XI (Paris-Saclay), where he graduated summa cum laude for research performed at Massachusetts General Hospital and Harvard Medical School. Greg received a B.S. in biology from the University of Massachusetts, Amherst.